The latest domestic launch news of Daridorexant in 2025

Daridorexant is a new drug used to treat insomnia, especially those caused by difficulty falling or staying asleep. The drug is currently on the market in many countries and regions, but has not yet been approved in mainland China. Despite this, the potential of DaliRasen in treating insomnia has received widespread attention, and it is expected that it may be introduced into the Chinese market in the future. Since this drug is not currently on the market in China, patients usually need to purchase it through overseas channels if they need it.

Abroad, the original drug of DaliRasen has been officially launched. Taking Europe as an example, the price of the European version of Dali Rayson is about more than 2,000 yuan. Compared with other similar drugs, DaliRasen has certain advantages in efficacy and can help patients effectively improve sleep quality and reduce the problem of premature or frequent waking up. Due to its outstanding curative effect, the demand for DaliRasen in foreign markets is gradually growing, especially in those countries and regions with a high proportion of insomnia patients.

Although the original drug of DaliRasen is already on the market in foreign markets, there is currently no generic version of the drug. This means that patients can only choose to buy original drugs, and the price is relatively high. For patients with heavy financial burdens, purchasing original drugs may cause certain financial pressure. Therefore, the launch of generic drugs will be of great significance in reducing treatment costs and improving drug accessibility. However, there are currently no generic drugs available, and patients can only purchase them through formal import channels.

With the gradual promotion of DaliRasen in the global market, it is expected that more generic drug manufacturers may enter the market in the future to cope with the growing demand. In the Chinese market, the drug approval process is usually complicated, but as China continues to optimize its new drug approval policy, the introduction of DaliRasen may also be approved in the near future. For domestic patients, understanding the latest drug launch trends and purchasing drugs through legal channels will be important factors in ensuring treatment effectiveness and drug safety.

Reference materials：https://www.quviviq.com/